Related Experiment Video
Updated: May 23, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Does early surfactant improve outcome in late preterm newborn? Retrospective study in a neonatal intensive care unit
Jorge Bartual Bardisa1, Carolina Vizcaíno Díaz1, María Jesús Ferrández Berenguer1
1Servicio de Pediatría, Hospital General Universitario de Elche, Elche, Alicante, Spain.
Objective:
To compare the early administration of surfactant, before 12 h of life, versus late, in late preterm neonates (born between 34+0 and 36+6 weeks of gestation), with moderate-severe respiratory distress.
Design:
Retrospective, observational, analytical, case-control study, with late preterm infants admitted between 2012-2021. It is divided into 2 groups: surfactant administered ≤ 12 h of life and >12 h and evolution is compared using univariate analysis.
Setting:
Neonatal Intensive Care Unit (NICU) level III of a Universitary Hospital.
Patients Or Participants:
57 patients, 30 in the early group and 27 in the late group.
Inclusion Criteria:
neonates from 34+0 to 36+6 weeks of gestation, with respiratory distress syndrome, in need of non-invasive ventilation and surfactant.
Interventions:
None.
Main Variables Of Interest:
Sociodemographic, clinical and evolutionary: redosing, duration of respiratory support, oxygen and time to stop requiring it after surfactant. Also, complications and length of hospitalization.
Results:
In the early group there was less need for redosing (3.3% vs 48.1%, P < .001) and a decrease in duration, in days, of stay in the NICU (7 vs 10.5, P .002), invasive mechanical ventilation (2.4 vs 3.9, P .034), total respiratory support (4.6 vs 6.6, P .005) and oxygen therapy (0.4 vs 2.8, P < .001). Also, lower incidence of pneumothorax (0% vs 33.3%, P .001). Furthermore, 12 h after administration, 83.4% maintained FiO2 0.21, compared to 44.4% in the late administration.
Conclusions:
In our study, early administration in late preterm infants provides benefits in terms of respiratory assistance and complications. We suggest expanding studies to establish recommendations in this group of patients.

